Sector News

Less than a year in, 'action-oriented' Teva CEO Schultz has analysts impressed

June 27, 2018
Life sciences

Teva’s mega-cost-cutting drive hasn’t been popular with workers or its home country of Israel. Analysts, on the other hand, like what they’ve seen so far from the company’s new executives.

These days, Teva is “led by action-oriented leaders with a rapid and clear path to recovery,” Goldman Sachs’ Jami Rubin wrote in a note to clients after meeting with CEO Kåre Schultz and company last week. Compare that with ex-CEO Erez Vigodman’s C-suite, which Rubin characterized as “fairly reactionary and directionless,” and it makes for a “stark shift.”

So much so, in fact, that Rubin has recommended since December that investors buy Teva’s shares, despite the pricing pressure that continues to wreak havoc on the generics industry and the “limited track record” of the knockoff giant’s new management team.

“While still early in the turnaround phase, our confidence in the de-leveraging story and increasingly clear line of sight to growth (beginning in 2020) keeps us Buy rated,” she wrote.

Rubin isn’t alone. Earlier this year, Credit Suisse analyst Vamil Divan, M.D., upgraded Teva’s shares, pointing to “early signs of execution” on the $3 billion restructuring plan that’s set to claim 14,000 jobs.

Schultz, for his part, hasn’t tried to hide his own opinion of the way Teva’s former leaders handled the company. For one, they created a bloated corporate structure with too many layers, he said at January’s J.P. Morgan Healthcare Conference, and they grew through acquisitions in a way that Schultz found “very suboptimal from a cost-efficiency point of view.”

On top of that, “Teva used to focus on maximizing revenue in the generics business believing that if you just maximize revenue, everything will fall into place and you’ll get great profitability and so on,” Schultz said, stressing that instead, “you always need to maximize operating profit.”

Those philosophies helped Schultz, a veteran of Novo Nordisk and the former skipper at Lundbeck, land the Teva CEO job, along with a $17 million pay package the likes of which Teva’s top executives have never seen. And the way Rubin sees it, after Schultz has eased Teva’s debt and pared down costs, there will be plenty of opportunity for new products to chip in growth.

Neuro drug Austedo, for one, is “just scratching the surface” of a “huge” market for tardive dyskinesia, which Rubin thinks could make the product a blockbuster seller. And forthcoming migraine drug fremanezumab “could drive meaningful upside to EBITDA and cash flow for speedier debt repayment”—particularly if it launches this fall, as Teva executives expect.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.